Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
SpaceX Seeks FCC Approval for Massive Solar-Powered Satellite Network to Support AI Data Centers 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
CAMBRIDGE, Mass., May 30, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, today announced that it is scheduled to present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 13 at 10:40 a.m. PT (1:40 p.m. ET). Edward Kaye, Sarepta’s chief executive officer, will be the presenter at the fireside chat.
The presentation will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
